{"disease":{"id":"grade-2-meningioma","name":"grade 2 meningioma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03180268","title":"Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":163,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT04082520","title":"Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":41,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03604978","title":"Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":38,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}